The incidence of acquired aplastic anaemia (AA) peaks in adolescents and young adults (AYA). Although age has been associated with response after immunosuppressive therapy (IST), few data exist about the specific outcome of AYA. We retrospectively compared the outcome of 29 children (aged <15 years), 32 AYA (15-25 years) and 23 adults (>25 years) with AA treated front-line with IST in Saint-Louis Hospital. The cumulative incidence of response was lower in adults compared with AYA (subdistribution hazard ratio [SHR] = 0Á38, 95% confidence interval [CI] [0Á96-1Á00], P = 0Á008), but no difference was observed between children and AYA (SHR = 0Á84, 95% CI [0Á96-1Á00], P = 0Á56), with a 6 months cumulative incidence of partial response of 44Á8% in children, 62Á5% in AYA and 21Á7% in adults. The 5-year failure-free survival was 48Á4%, without impact of age, with a 5-year relapse rate of 20Á7%. With a median follow-up of 5Á4 years, the 5-year overall survival was 86Á5%, without significant difference between children and AYA overall survival (hazard ratio [HR] 1Á51, 95% CI [0Á25-9Á02], P = 0Á66), while adults displayed poorer survival than AYA (HR 4Á98, 95% CI [1Á00-24Á73], P = 0Á049). This study confirms that age is a prognostic factor in AA patients treated with IST. However, AYA patients have a similar outcome to children in terms of response rate and survival.
Summary
The incidence of acquired aplastic anaemia (AA) peaks in adolescents and young adults (AYA). Although age has been associated with response after immunosuppressive therapy (IST), few data exist about the specific outcome of AYA. We retrospectively compared the outcome of 29 children (aged <15 years), 32 AYA (15-25 years) and 23 adults (>25 years) with AA treated front-line with IST in Saint-Louis Hospital. The cumulative incidence of response was lower in adults compared with AYA (subdistribution hazard ratio [SHR] = 0Á38, 95% confidence interval [CI] [0Á96-1Á00], P = 0Á008), but no difference was observed between children and AYA (SHR = 0Á84, 95% CI [0Á96-1Á00], P = 0Á56), with a 6 months cumulative incidence of partial response of 44Á8% in children, 62Á5% in AYA and 21Á7% in adults. The 5-year failure-free survival was 48Á4%, without impact of age, with a 5-year relapse rate of 20Á7%. With a median follow-up of 5Á4 years, the 5-year overall survival was 86Á5%, without significant difference between children and AYA overall survival (hazard ratio [HR] 1Á51, 95% CI [0Á25-9Á02], P = 0Á66), while adults displayed poorer survival than AYA (HR 4Á98, 95% CI [1Á00-24Á73], P = 0Á049). This study confirms that age is a prognostic factor in AA patients treated with IST. However, AYA patients have a similar outcome to children in terms of response rate and survival.
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Acquired aplastic anaemia (AA) is a rare haematological disease characterized by peripheral blood cytopenia and hypocellular bone marrow (Montan e et al, 2008; Young & Kaufman, 2008) . Most cases are considered idiopathic, though paroxysmal nocturnal haemoglobinuria (PNH) clone is found in about 30% of cases and 5-10% of AA occur following seronegative hepatitis (Brown et al, 1997; Young, 2002) . In this disease, a mechanism of immune-mediated destruction of haematopoietic stem cells by T cells with a T-helper type 1 cytokine profile, resulting in bone marrow failure, has been suggested (Young et al, 2006) . Allogeneic haematopoietic stem cell transplantation (HSCT) from a human leucocyte antigen-identical sibling donor is considered as the best option for patients younger than 40 years old with acquired AA requiring treatment, (Marsh et al, 2009) leading to 75-90% long term cure rates (Deeg et al, 1998; Horowitz, 2000; Bacigalupo et al, 2015) . In patients aged over 40 years or in those lacking a matched-related donor, immunosuppressive therapy (IST) combining horse or rabbit anti-thymoglobulin (ATG) and ciclosporin A (CSA) results in a 60-80% response rate and 75-90% 5-year overall survival (OS) (Bacigalupo et al, 2000a,b; Frickhofen et al, 2003; Locasciulli et al, 2007; Peffault de Latour et al, 2018) . However, most AA patients are not cured by IST: around 30% of responders will fail to achieve complete response (CR), 30% of responders will be CSA-dependent and 30% will relapse. Finally, 10-15% will present a clonal evolution, such as myelodysplastic syndrome or acute myeloid leukaemia (Afable et al, 2011a) . Blood counts are the major predictors of outcome in AA patients and residual levels of reticulocytes and lymphocytes have correlated with both response to ATG and survival. Haematological response rates after immunosuppressive therapies are higher among children than adults (Scheinberg et al, 2008) , and are worse among older adults (Tichelli et al, 1999) .
The age distribution of acquired AA is biphasic, with a first peak of incidence in adolescents and young adults (AYA) (Montan e et al, 2008; Young & Kaufman, 2008) , but little is known about the specific outcome of AYA patients with AA (Dufour et al, 2014) . It has been shown that the AYA population with chronic disease has specific features, outcomes and treatment strategies (Steinbeck et al, 2014) . AYA life is marked by major physical, psychological, emotional and social changes, which could impact care and disease outcome (Steinbeck et al, 2014) . When non-adherence (NA) rates are examined, the evidence suggests that adolescents are consistently less adherent than younger or older patients with cancer, even when treated with similar protocols for similar diseases (Leader & Raanani, 2014) . In this population, NA is a major issue, especially when a long-term daily oral treatment is required, such as CSA in AA, tyrosine-kinase inhibitors (TKI) in chronic myeloid leukaemia (Pemmaraju et al, 2012) or maintenance therapy in acute lymphoblastic leukaemia (Bhatia et al, 2012) .
In this report, we retrospectively analysed a wide age-range population of patients treated front-line with CSA and ATG, and compared the outcome of AYA (aged 15-25 years) with that of children (aged <15 years) and adults (aged >25 years).
Patients and methods

Study design
Patients referred to Saint-Louis Hospital between January 2000 and June 2013, with a diagnosis of AA requiring treatment were retrospectively analysed. Inclusion criteria were: (i) diagnosis of acquired AA, (ii) first line treatment with immunosuppressive using the ATG-CSA regimen. Exclusion criteria were: (i) front line allogeneic HSCT, (ii) inherited bone marrow failure (IBMF), (iii) immunosuppressive therapy without ATG. Patients who received androgen therapy and/or corticosteroids before the ATG-CSA regimen were not excluded.
Bone marrow aspiration and biopsy, including cytogenetic study, and PNH clone detection were performed in all patients. IBMF syndromes were ruled out on the basis of clinical findings, such as family history and physical abnormalities (including short stature), morphological evaluation (cardiac and renal ultrasound) and available relevant laboratory tests, including alpha-fetoprotein, fetal haemoglobin, chromosomes breakage evaluation either spontaneous or after mitomycin C exposure, FANCD2 functional test and telomere length assessment for the most recent cases. . CSA was administrated orally at a dose of 10 mg/kg/day in two doses from day 1 and then adjusted to maintain a CSA residual level of 200-400 ng/ml. CSA was given at full dose for a minimal of 6 months and then slowly tapered according to physician's practice for a minimum total duration of 12 months. Methylprednisolone was given at the initial dose of 1 mg/kg/day, with tapering over a total of 4 weeks. Some patients received granulocyte colony-stimulating factor subcutaneously at 5 lg/kg/day for several months post-IST.
Treatment
Definitions
Aplastic anaemia (AA) was defined as pancytopenia with hypocellular bone marrow in the absence of an abnormal infiltrate and with no increase in reticulin. Severe AA (SAA) was defined according to the Camitta criteria (Camitta et al, 1976) as bone marrow cellularity of less than 30% and severe pancytopenia with at least two of the following peripheral blood count criteria : absolute neutrophil count (ANC) <0Á5 9 10 9 /l, absolute reticulocyte count (ARC) <0Á2 9 10 9 / l, platelet count <20 9 10 9 /l. Very severe AA was defined by previous criteria and ANC <0Á2 9 10 9 /l. Partial response (PR) was defined as no longer meeting criteria for SAA and no transfusion requirement. Complete response (CR) was defined by National Institutes of Health (NIH) criteria as haemoglobin level >100 g/l, ANC >1Á0 9 10 9 /l and platelet count >100 9 10 9 /l without any transfusion (Rosenfeld et al, 2003; Scheinberg et al, 2011) .
Relapse was defined as a decrease in blood counts requiring either the reintroduction of transfusions, IST or proceeding to HSCT. Clonal evolution was defined as the appearance of an additional cytogenetic abnormality or characteristic myelodysplastic-related morphological changes on bone marrow aspirate smears. A prior history of seronegative hepatitis in the months before AA defined post-hepatitis AA.
For the analyses, patients were divided into three age groups: children (aged <15 years), AYA (aged 15-25 years) and adults (aged >25 years).
Statistical analysis
Patients' characteristics and 6-month response rate among age groups were compared by Fisher exact test (categorical variables) or Kruskal-Wallis test (continuous variables). Cumulative incidence of PR and CR was the time between treatment and at least PR or CR, respectively, with HSCT and death considered as competing risks. Cumulative incidence of relapse was the time between PR reached upon IST to relapse, considering clonal evolution, HSCT or death after response as competing risks. Actuarial survival was calculated according to Kaplan and Meier. Failure-free survival (FFS) was defined as survival without failure. Death, lack of response, relapse or disease progression requiring second line of treatment, clonal evolution and evolution to PNH were considered treatment failures. The Fine and Gray hazard model for cumulative incidence of response was used to evaluate potential prognostic factors. Variables analysed in univariate and multivariate models were sex, age at diagnosis considered as 3 subgroups or as continuous variable, Camitta classification, baseline blood count (continuous variable), aetiology (PNH and post-hepatitis versus idiopathic), transfusions before ATG, ATG-type (rabbit versus horse) and time between diagnosis and ATG. Significant variables in univariate analysis were included in the multivariate model, where the Cox proportional hazard regression model was used. A P value of 0Á05 or less indicated statistical significance. Statistical analyses were performed using STATA/SE 11.0 (StataCorp, College Station, TX, USA) software.
Results
Patients' characteristics
Between 2000 and 2013, 84 patients attending our institution were included in the study: 29 (34Á5%) children, 32 (38Á1%) AYA, and 23 (27Á4%) adults. Median age was 17Á6 years (range 3Á4-65Á0) and sex ratio was 1. Clinical and biological characteristics of patients according to age group are summarized in Table I . Children presented more frequently with very SAA (55Á0% vs. 22Á0% in AYA and 22Á0% in adults, P = 0Á02), though baseline blood counts analysed separately were similar in the 3 groups. Thirteen percent of AAs were associated with a PNH clone, and 8Á3% were post-hepatitis AA, without significant difference between age groups. Most patients received transfusion before ATG (82Á1% RBC and 89Á3% platelet transfusions). Time from diagnosis to ATG was longer in adults (69 days vs. 26 in children and 28 in AYA, P = 0Á007). Children were more frequently treated with rabbit-ATG (86Á0% vs. 59Á0% in AYA and 52Á0% in adults, P = 0Á004).
Response
A total of 43 of the 84 patients (51Á2%) achieved at least a PR at 6 months after first-line IST, and 58 had achieved at least a PR (69%) at 2 years. The cumulative incidence of response was lower in patients aged over 25 years than in AYA patients (subdistribution hazard ratio [SHR] = 0Á38, 95% confidence interval [CI] [0Á96-1Á00], P = 0Á008), but no difference was observed between children and AYA (SHR = 0Á84, 95% CI [0Á96-1Á00], P = 0Á56) (Table II) . Thus, the estimated 6-month cumulative incidence of response was 44Á8%, 62Á5% and 21Á7% in children, AYA and adult populations respectively, and 69Á0%, 78Á1% and 43Á5% at 12 months ( Fig 1A) . In multivariate analysis, age remained associated with response, with a lower cumulative incidence of response in adults when compared with AYA patients (SHR = 0Á43, 95% CI [0Á21-0Á90], P = 0Á025), but no significant difference was observed between children and AYA (SHR = 0Á88, 95% CI [0Á48-1Á60], P = 0Á67). The ARC was the only other variable associated with response in multivariate analysis (SHR = 1Á11 for a 1Á0 9 10 9 /l increase, 95% CI [1Á02-1Á22], P = 0Á018) (Table II) . There was no difference in term of incidence of CR between the 3 age groups, with a 12-month estimate of 25Á0% in AYA, 20Á7% in children (SHR = 0Á99, 95% CI [0Á45-2Á18], P = 0Á99) and 17Á4% in adults (SHR = 0Á57, 95% CI [0Á22-1Á51], P = 0Á26) (Fig 1B) .
Relapse
Among the 58 patients who achieved at least PR, 17 patients relapsed (9 children, 7 AYA and 1 adult), within a median time of 2Á8 years (range 21Á0 days to 6Á4 years), leading to a 5-year cumulative incidence of 20Á7%: 20Á0% in AYA, 27Á3% in children (SHR = 1Á40, 95% CI [0Á52-3Á78], P = 0Á50) and 9Á1% in adults (SHR = 0Á31, 95% CI [0Á04-2Á56], P = 0Á27) with no significant difference among age subgroups (Fig 2) . Higher baseline ALC was the only parameter correlated with relapse (HR = 1Á94 for a 1Á0 9 10 9 /l increase, 95% CI [1Á16-3Á34], P = 0Á011).
Clonal evolution and transplantation
Four patients (4Á7%) developed clonal evolution after IST within a median time of 1Á5 years. Three patients developed a monosomy 7 before transformation into acute myeloid leukaemia (AML). One patient acquired a deletion 13q without bone marrow dysplasia. In this cohort, 27 patients (32Á1%) underwent HSCT after the first line treatment for IST failure (59Á3%), relapse (29Á6%) or AML transformation (11Á1%): 13 in children, 7 in AYA, and 7 in adults. Sixty-three percent of transplanted patients underwent a matched unrelated donor HSCT, 15% a matched sibling donor HSCT and 19% were transplanted with unrelated cord blood.
Survival
With a median follow-up of 5Á4 years (range 0Á7-14Á6), the FFS was 58Á8% at 2 years (64Á5% in children, 65Á1% in AYA and 42Á5% in adults) and 48Á4% at 5 years (50Á1%, 56Á4% and 35Á4 respectively), without statistical difference between the 3 age groups. When comparing AYA versus children, HR was 1Á17 (95% CI [0Á59-2Á35], P = 0Á65) and 1Á64 for AYA versus adults (95% CI [0Á79-3Á41], P = 0Á19) (Fig 3A) . A higher baseline ALC was the only parameter that correlated with poorer FFS (HR = 1Á63, 95% CI [1Á17-2Á27], P = 0Á004) (Fig 3B) . The 2-and 5-year overall A. Cabannes-Hamy et al survival (OS) was 91Á3% and 86Á5%, respectively. When censoring patients at time of HSCT, 5-year OS was 95Á9% (Fig 3D) . Eleven patients died (3 children, 2 AYA and 6 adults) within a median time between diagnosis and death of 1Á8 years (range 0Á8-10Á1). Most deaths (N = 8) occurred after HSCT performed as salvage therapy after IST failure (N = 5), relapse (N = 2) or AML transformation (N = 1). The 5-year OS after HSCT was 66Á0%. The remaining causes of deaths were infections in 2 patients and unknown in 1 patient. The 3 non-transplanted deaths occurred in adults. Children and AYA displayed similar 5-year OS with 88Á1% vs. 93Á1% respectively (HR 1Á51, 95% CI [0Á25-9Á02], P = 0Á66). However, the adult population had a shorter survival than AYA with a 5-year OS of 77Á1% vs. 93Á1% (HR 4Á98, 95% CI [1Á00-24Á73], P = 0Á049) (Fig 3C) . Age was the only predictive factor associated with survival.
Adherence
Focusing on the AYA population, we retrospectively registered the physician-reported compliance data in patients' medical records: 55 (65Á5%) patients were considered as having good compliance, 11 (13Á6%) were recorded as poorer adherers while data were missing in 18 patients (21Á4%). In the AYA population, 24Á1% of patients were poorer adherers, compared with 13Á6% in children and 6Á7% in adults. But, despite a seemingly lower adherence to treatment in AYA population, these patients did not present increased incidence of treatment failure or relapse. 
Discussion
Younger age has been associated with better response and survival in several studies of patients with acquired AA treated by a combination of ATG and CSA (Tichelli et al, 1999; Rosenfeld et al, 2003; Sugimori et al, 2006; Scheinberg et al, 2009) . However, few data exist on the specific outcome of AYA patients. In this study, focusing on this population, we compared outcome of AYA patients treated in first line by ATG-CSA with that of younger and older patients. In this mainly young population (median age, 17Á4 years), younger age was highly associated with better response to IST. These results are consistent with 2 reports from the NIH showing an association between age and response rate, in both an adult population, with median age over 30 years (Scheinberg et al, 2009) , and a paediatric population (Scheinberg et al, 2008) . In contrast, in a large European cohort including older patients, there was no correlation between response to treatment and age (Tichelli et al, 1999) . These contrasting results could be explained by the heterogeneity of the studied populations in term of age (Tichelli et al, 1999) . Several hypotheses could explain the relationship between response to IST and age. First, acquired AA typically refers to 2 populations of patients according to age with different characteristics, which could suggest a different pathophysiology and therefore a different response to IST. The first peak of incidence occurs in AYA patients, mainly male, with mostly severe cases, a short time between diagnosis and treatment, and a better response to treatment. The second peak concerns patients aged over 60 years, involving mostly women with non-severe cases, a long interval between diagnosis and IST, and a lower response rate (Mary et al, 1990) . We observed a significantly longer interval between diagnosis and treatment in oldest patients, and more very SAA disease in children, associated with a high response rate after IST. Our data are consistent with a paediatric study reporting a better response in very SAA, (F€ uhrer et al, 2005) and with a Japanese study describing a long period between diagnosis and treatment, associated with a poorer response (Jeong et al, 2014) .
We confirmed the relationship between a higher baseline ARC and a better response to treatment, as previously shown ALC, absolute lymphocyte count; ANC, absolute neutrophil count; ARC, absolute reticulocyte count; ATG, anti-thymoglobulin; Hb, haemoglobin; PC, platelet concentrate; PNH, paroxysmal nocturnal haemoglobinuria; RBC, red blood concentrate; SHR, sub-hazard ratio.
in a NIH report, where patients with an elevated ARC had a 40% higher response rate compared to other patients (Scheinberg et al, 2009) . Robust recovery of the reticulocyte count following immunosuppressive treatment has been described to predict long-term survival (Rosenfeld et al, 2003) .These data suggest that baseline ARC may help in clinically assessing bone marrow function and that better residual marrow function can support blood cell production after IST. Thus, low ARC, which is a Camitta criterion for defining SAA, remains associated with patient outcome after IST. The 20Á7% 5-year relapse rate observed in this study is fairly similar to previous published data (Tichelli et al, 1999; Scheinberg et al, 2008; Dufour et al, 2014) . Age group at diagnosis did not influence relapse rate, nor age analysed as a timedependent parameter (data not shown). Despite a seemingly lower adherence to treatment in the AYA population compared with children and adults, these patients did not present increased incidence of treatment failure or relapse. However, due to the retrospective nature of this work, the adherence evaluation was incomplete and should be carefully interpreted.
Although the 5-year OS rate of 86Á5% was similar to the most recent reports (Peffault de Latour et al, 2018) , IST in first-line therapy only led to a 5-year FFS of 48Á4%. The prolonged survival of most patients in failure or in relapse after IST could be explained by the efficacy of second line treatment, such as second IST or HSCT, and progresses achieved in supportive care, including transfusions and antifungal prevention. Given that HSCT was performed as salvage therapy in patients mostly lacking a matched related donor, the 65% 5-year OS was encouraging and also consistent with recent data (Maury et al, 2007; Bacigalupo et al, 2015) . As previously reported (Tichelli et al, 1999; Rosenfeld et al, 2003; Sugimori et al, 2006; Scheinberg et al, 2009 ), we showed that younger age was associated with better survival, with no difference observed between children and AYA, but poorer survival in patients older than 25 years. Surprisingly, we found an association between lower pretreatment ALC and lower relapse rate, leading to better FFS. These data contrast with previous studies, which reported a higher ALC as an independent positive predictor of response (Scheinberg et al, 2009 ) and/or survival (Scheinberg et al, 2009; Chang et al, 2010; Afable et al, 2011b) . Considering the immune-mediated destruction of haematopoietic stem cells by T lymphocytes, a lower baseline ALC could need less T-cell destruction to achieve haematological recovery after IST. Obviously, these results need to be confirmed and further explorations of T-cell subpopulations are required.
We didn't confirm the previously described superiority of horse-ATG compared with rabbit-ATG, in terms of response and survival in both adults and children (Scheinberg et al, 2011; Marsh et al, 2012; Yoshimi et al, 2013) . Of note, only 2 children of our cohort (6Á9%) received horse ATG versus 40% of patients aged over 15 years. However, even after including ATG type in the multivariate analysis model, age remained correlated with response, showing that this association was independent of the type of ATG used. In fact, we observed a marked trend toward a better 6-month response rate after horse ATG (data not shown), but this effect did not remain with longer follow-up, suggesting an earlier but not a better response with horse ATG.
Our study was limited by its retrospective, monocentric nature and quite small cohort. Furthermore, the total duration of IST, left to the discretion of physicians, could lead to a difficult evaluation of treatment compliance. However, during the 13-year period of inclusion, patients were referred to this centre from many French hospitals as part of the French Reference Centre for Aplastic Anaemia, and diagnostic and response criteria and follow-up remained unchanged.
In conclusion, our results confirmed that younger age is highly associated with better outcome after ATG-CSA in acquired AA. Response and OS rates in AYA are as good as those observed in children and better than those achieved by adults. Prospective and larger studies are still needed to better evaluate adherence and optimize the fine-tuning longterm management of AYA population.
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